Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 55.62M shares rose 33.1% year over year, ahead of the +13.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 19.6% from the prior quarter. Over 3 fiscal years it compounded at +5.3% a year.
Context
- Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +33.1% holds above the trailing-twelve-month pace of +13.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 44.73M USD
- Year-over-year change
- +7.0%
- 3-year CAGR
- +5.3%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.73M | +7.0% |
| FY2024 | 2024-12-31 | 41.79M | +9.1% |
| FY2023 | 2023-12-31 | 38.32M | +0.0% |
| FY2022 | 2022-12-31 | 38.32M | — |
Weighted Avg Shares (Diluted) vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's LTM Mar 2026 weighted avg shares (diluted) of 46.54M shares is the 6th highest of the 8 companies compared; the peer median is 59.14M shares.
- Its year-over-year change of +13.7% is the 4th highest of 7, against a peer median of +12.6%.
- Over three fiscal years its annual growth of +5.3% compares with a peer median of +18.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 199.36M | +24.0% | +14.0% | |
| LTM Mar 2026 | 161.69M | +14.3% | +41.6% | |
| LTM Mar 2026 | 124.17M | +37.8% | +23.4% | |
| FY2025 | 59.14M | +10.9% | +5.2% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | 54.07M | +4.2% | +14.0% |
| LTM Mar 2026 | 46.54M | +13.7% | +5.3% | |
| LTM Mar 2026 | 12.78M | +5.6% | +56.9% | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | 0 | — | — |
| Peer median (excluding ZBIO) | 59.14M | +12.6% | +18.7% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 50M | 5M | 10M |
| Cost of Revenue | 61.69M | 0 | 139.14M | 0 |
| Gross Profit | (61.69M) | 50M | (134.14M) | 10M |
| Gross Margin | — | 100.0% | -2682.8% | 100.0% |
| Research & Development | 62.69M | 60.03M | 139.14M | 168.06M |
| Selling, General & Admin | 13.51M | 17.11M | 29.75M | 53.32M |
| Operating Expenses | 14.51M | 87.15M | 29.75M | 221.39M |
| Depreciation & Amortization | 78K | 113K | 137K | 56K |
| EBITDA | (75.12M) | (27.03M) | (156.42M) | (370.43M) |
| EBITDA Margin | — | -54.1% | -3128.4% | -3704.3% |
| Operating Income | (76.2M) | (37.15M) | (163.89M) | (211.39M) |
| Operating Margin | — | -74.3% | -3277.8% | -2113.8% |
| Interest Income | 0 | 0 | 0 | 12.15M |
| Interest Expense | 0 | 0 | 0 | 7.33M |
| Other Income / Expenses | (43.08M) | 324K | 7.33M | (166.43M) |
| Income Before Tax | (119.28M) | (36.82M) | (156.56M) | (377.82M) |
| Pre-Tax Margin | — | -73.6% | -3131.2% | -3778.2% |
| Income Tax Expense | 0 | 301K | 429K | (79K) |
| Net Income | (119.28M) | (37.12M) | (156.99M) | (377.74M) |
| Net Margin | — | -74.2% | -3139.8% | -3777.4% |
| EPS (Basic) | (3.11) | (0.97) | (3.76) | (8.44) |
| EPS (Diluted) | (3.11) | (0.97) | (3.76) | (8.44) |
| Weighted Avg Shares | 38.32M | 38.32M | 41.79M | 44.73M |
| Weighted Avg Shares (Diluted) | 38.32M | 38.32M | 41.79M | 44.73M |
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.